Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study
ITEP
1 other identifier
interventional
240
1 country
1
Brief Summary
The risk of recurrence in stage III and IV of colorectal cancers (CRC) is high during the three years following the tumoral resection with curative aim. Therefore, a prolonged follow-up and an intense monitoring are recommended to detect these recurrences precociously. Nevertheless, current consensual morphological and biological examinations are not very contributory, of difficult interpretation and expensive. The metabolic imagery in tomoscintigraphy by emission of positron coupled with the scanner, called PET-TDM, allows to identify more specifically recurrences, analyzes the whole body, detects hepatic metastasis more precociously and give some benefice for early diagnosis of lymph nodes recurrence. The principle purpose of this study is to evaluate if the systematic follow-up per PET-TDM allows detecting more often recurrences accessible to a curative surgery. We make the hypothesis that the systematic practice of PET- tomodensitometry (TDM) during the follow-up of CRC allows to decrease non curative recurrences appearance during the 3 years follow-up after a curative surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable colorectal-cancer
Started Jun 2008
Longer than P75 for not_applicable colorectal-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 15, 2008
CompletedFirst Posted
Study publicly available on registry
February 27, 2008
CompletedStudy Start
First participant enrolled
June 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedMarch 18, 2016
March 1, 2016
7 years
February 15, 2008
March 17, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of patients with a non removable recurrence
at the end of the study
Secondary Outcomes (3)
Survival without non removable tumor
At the end of the study
Overall survival
At the end of the study
Cost of the strategy
At the end of the study
Study Arms (2)
2
ACTIVE COMPARATORUsual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
1
EXPERIMENTALSemi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
Interventions
PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
Eligibility Criteria
You may qualify if:
- Patients with a removed colorectal adenocarcinoma since less than 6 months, in total remission and for whom a monitoring is necessary to detect recurrences precociously.
- Patients with a T4N0M0 tumour and operated in emergency (because of a tumoral perforation) can be included. (suppressed by amendment 1)
- before criteria have been replaced by : Patients with colorectal adenocarcinoma which is histologically proved and classified stage II perforated, III or IV, totally removed, in total remission,
- if no metastatic, removed surgery must have been done since less 6 months;
- if metastatic, all metastasis would have been removed, the last surgery dating less 6 months.(amendment 1)
- Casual extension check-up would have been realized before initial surgery or during a period of 6 months after surgery performed in emergency.
- informed consent signed
- Age ≥ 18 years
- Patient in ability to undergone hepatic or pulmonary resection in case of recurrence during the follow-up (ECOG ≤ 2)
- Willingness to control visits
You may not qualify if:
- pregnant or breast feeding women, or with a reproductive potential and no practicing an effective method of contraception during the second part of ovarian cycle ( PET is realised during the first part of ovarian cycle)
- Cancer stage I or II (except T4 operated in emergency) or IV without possibility to remove metastasis or R2 after surgery.
- Performance status contraindicating a hepatic or pulmonary surgery in case of recurrence.
- Patients likely to undergone chemotherapy, surgery or radiotherapy during 2 weeks before PET-TDM.
- Other progressive tumoral affection known, or colorectal cancer in progression.
- (Bad compliance to the study procedure.)(suppressed by amendment 1)
- Not balanced diabetes. (added by amendment 1)
- Patients included in others clinical trials of imagery.
- Inability to provide informed consent signed.
- No social assurance.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Henri Mondor
Créteil, 94000, France
Related Publications (1)
Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, Andre T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031.
PMID: 29365058DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Iradj Sobhani, MD, PhD
Assistance Publique - Hôpitaux de Paris
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 15, 2008
First Posted
February 27, 2008
Study Start
June 1, 2008
Primary Completion
June 1, 2015
Study Completion
June 1, 2015
Last Updated
March 18, 2016
Record last verified: 2016-03